Figueiredo Costa Silvia
Shock. 2008 Oct;30 Suppl 1:23-9. doi: 10.1097/SHK.0b013e3181818990.
Antimicrobial therapy is one of the main stones of sepsis therapy. A recent study of septic shock patients showed that each hour of delay in antimicrobial administration during the ensuing 6 h after the onset of hypotension was associated with a decrease in survival rates. However, many questions regarding the impact of infection caused by antimicrobial-resistant pathogens on the mortality of patients with sepsis still need to be clarified. There is a lack of fair studies in the literature. Most studies have had inadequate sample size, inadequate adjustment for predictors of adverse outcomes, and inadequate definition of appropriate antibiotic therapy. Despite the fact that appropriate therapy is essential to treat sepsis, it seems that severity of underlying diseases and comorbidities are more important than resistance, although the studies were not well designed to examine the real impact of resistance on outcome. Finally, new technologies such as microarray that can identify different microorganisms, genes of resistance, and virulence in a few hours might have a great impact on the treatment of sepsis due to antimicrobial-resistant pathogens in the future.
抗菌治疗是脓毒症治疗的主要基石之一。最近一项针对感染性休克患者的研究表明,在低血压发作后的接下来6小时内,抗菌药物给药每延迟一小时,生存率就会降低。然而,许多关于耐抗菌性病原体引起的感染对脓毒症患者死亡率影响的问题仍有待阐明。文献中缺乏充分的研究。大多数研究样本量不足,对不良结局预测因素的调整不足,以及对适当抗生素治疗的定义不充分。尽管适当的治疗对于治疗脓毒症至关重要,但似乎基础疾病和合并症的严重程度比耐药性更重要,尽管这些研究在设计上并不完善,无法检验耐药性对结局的实际影响。最后,诸如微阵列等新技术能够在数小时内识别不同的微生物、耐药基因和毒力,未来可能会对耐抗菌性病原体引起的脓毒症治疗产生重大影响。